Log in

NASDAQ:CLBSCaladrius Biosciences Stock Price, Forecast & News

$1.93
+0.04 (+2.12 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.85
Now: $1.93
$1.98
50-Day Range
$1.70
MA: $2.03
$2.31
52-Week Range
$1.05
Now: $1.93
$3.64
Volume829,964 shs
Average Volume773,243 shs
Market Capitalization$24.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Read More
Caladrius Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLBS
CUSIPN/A
Phone908-842-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.98 per share

Profitability

Net Income$-19,360,000.00

Miscellaneous

EmployeesN/A
Market Cap$24.78 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter.

Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

How has Caladrius Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Caladrius Biosciences' stock was trading at $2.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLBS stock has decreased by 13.8% and is now trading at $1.93. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Caladrius Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Caladrius Biosciences.

When is Caladrius Biosciences' next earnings date?

Caladrius Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Caladrius Biosciences.

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences Inc (NASDAQ:CLBS) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.09. View Caladrius Biosciences' earnings history.

What price target have analysts set for CLBS?

4 analysts have issued twelve-month price targets for Caladrius Biosciences' shares. Their forecasts range from $6.00 to $18.50. On average, they expect Caladrius Biosciences' share price to reach $10.50 in the next year. This suggests a possible upside of 444.0% from the stock's current price. View analysts' price targets for Caladrius Biosciences.

Has Caladrius Biosciences been receiving favorable news coverage?

News stories about CLBS stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Caladrius Biosciences earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutCaladrius Biosciences.

Are investors shorting Caladrius Biosciences?

Caladrius Biosciences saw a drop in short interest in April. As of April 30th, there was short interest totaling 7,100 shares, a drop of 26.8% from the April 15th total of 9,700 shares. Based on an average daily volume of 30,800 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's stock are short sold. View Caladrius Biosciences' Current Options Chain.

Who are some of Caladrius Biosciences' key competitors?

What other stocks do shareholders of Caladrius Biosciences own?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the following people:
  • David J. Mazzo, President, Chief Executive Officer & Director
  • Joseph Talamo, CFO, Principal Accounting Officer & Senior VP
  • Douglas W. Losordo, Chief Medical Officer & Executive Vice President
  • Greg Berkin, Vice President-Information Technology
  • John D. Menditto, VP-Investor Relations & Corporate Communications

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

Who are Caladrius Biosciences' major shareholders?

Caladrius Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Summit Trail Advisors LLC (0.14%). View institutional ownership trends for Caladrius Biosciences.

Which major investors are buying Caladrius Biosciences stock?

CLBS stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC. View insider buying and selling activity for Caladrius Biosciences.

How do I buy shares of Caladrius Biosciences?

Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of CLBS stock can currently be purchased for approximately $1.93.

How big of a company is Caladrius Biosciences?

Caladrius Biosciences has a market capitalization of $24.78 million. The biotechnology company earns $-19,360,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

What is Caladrius Biosciences' official website?

The official website for Caladrius Biosciences is www.caladrius.com.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.